Liquid Biopsy as a Tool Exploring in Real-Time Both Genomic Perturbation and Resistance to EGFR Antagonists in Colorectal Cancer.
EGRF
cetuximab
colorectal cancer
liquid biopsy
panitumumab
resistance
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2020
2020
Historique:
received:
07
07
2020
accepted:
07
09
2020
entrez:
26
10
2020
pubmed:
27
10
2020
medline:
27
10
2020
Statut:
epublish
Résumé
The treatment of metastatic colorectal cancer (mCRC) has improved since the introduction of the epithelial growth factor receptor (EGFR) inhibitors as cetuximab and panitumumab. However, only patients with peculiar genomic profiles benefit from these targeting therapies. In fact, the molecular integrity of
Identifiants
pubmed: 33102237
doi: 10.3389/fonc.2020.581130
pmc: PMC7546030
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
581130Informations de copyright
Copyright © 2020 Internò, Tucci, Pezzicoli, Silvestris, Porta and Mannavola.
Références
Eur J Cancer. 2015 Mar;51(5):587-94
pubmed: 25673558
Clin Colorectal Cancer. 2015 Jun;14(2):115-22.e1-2
pubmed: 25680623
Nat Commun. 2015 Apr 30;6:7002
pubmed: 25926053
Ann Oncol. 2018 Jan 1;29(1):112-118
pubmed: 28950295
Ann Oncol. 2010 May;21(5):1006-12
pubmed: 19861577
BMC Cancer. 2017 Jun 9;17(1):408
pubmed: 28599628
Clin Chem. 2019 Nov;65(11):1405-1413
pubmed: 31551314
Ann Oncol. 2017 Dec 1;28(12):3009-3014
pubmed: 29045518
J Clin Oncol. 2010 Nov 1;28(31):4697-705
pubmed: 20921465
Ann Oncol. 2014 Sep;25(9):1756-1761
pubmed: 24942275
BMC Cancer. 2013 Dec 01;13:566
pubmed: 24289328
J Clin Oncol. 2019 Jun 10;37(17):1460-1469
pubmed: 30892987
Sci Rep. 2020 Feb 18;10(1):2813
pubmed: 32071364
Br J Cancer. 2013 Apr 2;108(6):1358-67
pubmed: 23470469
Mol Oncol. 2019 Apr;13(4):781-791
pubmed: 30556647
PLoS One. 2017 Nov 21;12(11):e0188174
pubmed: 29161279
Cancer Cell. 2017 Feb 13;31(2):172-179
pubmed: 28196593
Oncotarget. 2016 May 10;7(19):27848-54
pubmed: 27036043
J Clin Oncol. 2008 Dec 10;26(35):5705-12
pubmed: 19001320
Cancer Discov. 2011 Nov;1(6):508-23
pubmed: 22586653
PLoS One. 2018 Mar 16;13(3):e0194630
pubmed: 29547634
Anticancer Res. 2013 Sep;33(9):3905-10
pubmed: 24023327
Lancet Oncol. 2010 Aug;11(8):753-62
pubmed: 20619739
Ther Adv Med Oncol. 2018 Aug 29;10:1758835918794630
pubmed: 30181785
Oncol Lett. 2017 May;13(5):3608-3616
pubmed: 28521461
Lancet Oncol. 2014 Sep;15(10):1065-75
pubmed: 25088940
Biol Pharm Bull. 2019;42(3):337-342
pubmed: 30828064
Ann Oncol. 2015 Jan;26(1):13-21
pubmed: 25115304
Cancer Discov. 2016 Feb;6(2):147-153
pubmed: 26644315
Nat Rev Clin Oncol. 2013 Aug;10(8):472-84
pubmed: 23836314
Nature. 2012 Jun 28;486(7404):537-40
pubmed: 22722843
Int J Mol Sci. 2019 Dec 20;21(1):
pubmed: 31861757
Pharmacol Res. 2018 Oct;136:35-44
pubmed: 30142423
Clin Sci (Lond). 2020 Apr 30;134(8):955-959
pubmed: 32313957
JAMA Oncol. 2019 Mar 1;5(3):343-350
pubmed: 30476968
Sci Transl Med. 2016 Jul 6;8(346):346ra92
pubmed: 27384348
Clin Sci (Lond). 2020 Feb 28;134(4):419-434
pubmed: 32065214
Cancer Lett. 2013 Jul 10;335(1):225-31
pubmed: 23419522
Gut. 2018 Nov;67(11):1995-2005
pubmed: 28982739
Clin Chem. 2013 Jan;59(1):211-24
pubmed: 23065472
Nat Rev Clin Oncol. 2009 Sep;6(9):519-27
pubmed: 19636327
Br J Cancer. 2013 Dec 10;109(12):3067-72
pubmed: 24263065
Cancer Sci. 2019 Aug;110(8):2590-2599
pubmed: 31169336
Cancer Discov. 2014 Nov;4(11):1269-80
pubmed: 25293556
Ther Adv Med Oncol. 2020 Mar 13;12:1758835920905415
pubmed: 32206092
Oncoimmunology. 2017 Nov 6;7(2):e1387706
pubmed: 29308314
Clin Chem. 2016 Aug;62(8):1129-39
pubmed: 27251038
Int J Mol Sci. 2016 Oct 24;17(10):
pubmed: 27783057
Mol Oncol. 2014 Sep 12;8(6):1084-94
pubmed: 24913799
Expert Rev Mol Diagn. 2018 Jan;18(1):7-17
pubmed: 29115895
Int J Cancer. 2015 Sep 15;137(6):1467-74
pubmed: 25704501
Sci Transl Med. 2020 Jan 1;12(524):
pubmed: 31894106
BMC Cancer. 2012 May 16;12:178
pubmed: 22591372
PLoS One. 2009 Oct 02;4(10):e7287
pubmed: 19806185
Ann Oncol. 2015 Aug;26(8):1715-22
pubmed: 25851626
Sci Transl Med. 2014 Feb 19;6(224):224ra24
pubmed: 24553385
Mol Oncol. 2016 Mar;10(3):475-80
pubmed: 26774880
Mol Aspects Med. 2020 Apr;72:100816
pubmed: 31377345
J Transl Med. 2019 Jul 19;17(1):230
pubmed: 31324252
Am J Med Sci. 2018 Mar;355(3):220-227
pubmed: 29549923
J Clin Oncol. 2008 Jul 1;26(19):3213-21
pubmed: 18591556
Clin Cancer Res. 2019 Apr 1;25(7):2254-2263
pubmed: 30617129
Sci Rep. 2019 Nov 21;9(1):17276
pubmed: 31754145
Lab Chip. 2018 Apr 17;18(8):1174-1196
pubmed: 29569666
Cancer Treat Rev. 2013 Nov;39(7):759-72
pubmed: 23375250
J Extracell Vesicles. 2018 Nov 23;7(1):1535750
pubmed: 30637094
Cancer Cell Int. 2018 Oct 22;18:164
pubmed: 30377411
Front Oncol. 2012 Aug 09;2:96
pubmed: 22934287
Oncotarget. 2016 Sep 13;7(37):59058-59069
pubmed: 27340863
J Clin Oncol. 2014 Jul 20;32(21):2240-7
pubmed: 24687833
Nat Rev Clin Oncol. 2017 Sep;14(9):531-548
pubmed: 28252003
Ann Oncol. 2017 Aug 1;28(8):1713-1729
pubmed: 28407110
Front Oncol. 2019 Jun 19;9:521
pubmed: 31275854
JAMA Oncol. 2019 Oct 17;:
pubmed: 31621801
Clin Chem. 2013 Jan;59(1):252-60
pubmed: 23136247
Am Soc Clin Oncol Educ Book. 2018 May 23;38:978-997
pubmed: 30231331
Pathobiology. 2018;85(1-2):146-154
pubmed: 28614831
Oncotarget. 2018 Apr 17;9(29):20826-20837
pubmed: 29755693
Br J Cancer. 2015 Jun 9;112(12):1888-94
pubmed: 25989278
Int J Cancer. 2018 Aug 15;143(4):907-920
pubmed: 29542109